Inhibitory effects of bucillamine on the expression of vascular cell adhesion molecule-1 in human umbilical vein endothelial cells

International Immunopharmacology

Volumn 4, Issue 1, 2004, Pages 119-126

  Kikuchi, Hirotoshi ^a   Isshi, Kunio ^a   Hirohata, Shunsei ^a  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adhesion molecules; Bucillamine; E selectin; Endothelial cells; ICAM 1; Rheumatoid arthritis; TNF ; VCAM 1

Indexed keywords

BUCILLAMINE; CD34 ANTIGEN; DISULFIDE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEPARIN; INTERCELLULAR ADHESION MOLECULE 1; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ARTICLE; BONE MARROW CELL; CELL CULTURE; CELL GROWTH; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CULTURE MEDIUM; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; ENDOTHELIUM CELL; HUMAN; HUMAN TISSUE; INCUBATION TIME; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SOLUBILITY; STATISTICAL SIGNIFICANCE; UMBILICAL VEIN;

EID: 1242284229     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2003.11.002     Document Type: Article

References (25)

1. Shiokawa Y., Abe C., Warabi S., Abe H., Kageyama T.et al. Clinical evaluation of SA96 on rheumatoid arthritis (in Japanese). Jpn. J. Inflamm. 5:1985;333-343.
2. Abe C. Clinical evaluation of immunomodulators. Int. J. Immunother. 1:1985;7-10.
3. Kashiwazaki S., Shiokawa Y. Bucillamine: a new immunomodulator. Int. J. Immunother. 3:1987;1-6.
4. Hirohata S., Lipsky P.E. Regulation of B cell function by bucillamine, a novel disease-modifying antirheumatic drug. Clin. Immunol. Immunopathol. 66:1993;43-51.
5. Hirohata S., Lipsky P.E. Comparative inhibitory effects of bucillamine and D-penicillamine on the function of human B cells and T cells. Arthritis Rheum. 37:1994;942-950.
6. Schumacher H.R. Jr., Bautista B.B., Krauser R.E., Mathur A.K., Gall E.P. Histological appearance of the synovium in early rheumatoid arthritis. Semin. Arthritis Rheum. 23(Suppl. 2):1994;3-10.
7. Koch A.E. Angiogenesis: implications for rheumatoid arthritis. Arthritis Rheum. 41:1998;951-962.
8. Cronstein B.N., Weissmann G. The adhesion molecules of inflammation. Arthritis Rheum. 36:1993;147-157.
9. Springer T.A. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell. 76:1994;301-314.
10. Nagashima M., Yoshino S., Aono H., Takai M., Sasano M. Inhibitory effects of anti-rheumatic drugs on vascular endothelial growth factor in cultured rheumatoid synovial cells. Clin. Exp. Immunol. 116:1999;360-365.
11. Koyama S., Takagi H., Otani A., Oh H., Nishimura K., Honda Y. Inhibitory mechanism of vascular endothelial growth factor (VEGF) by bucillamine. Br. J. Pharmacol. 137:2002;901-909.
12. Marui N., Offermann M.K., Swerlick R., Kunsch C., Rosen C.A.et al. Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. J. Clin. Invest. 92:1993;1866-1874.
13. Arnett F.C., Edworthy S.M., Bloch D.A., McShane D.J., Fries J.F.et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31:1998;315-324.
14. Ueda T., Tsuji K., Yoshio H., Ebihara Y., Yagasaki H.et al. Expansion of human NOD/SCID-repopulating cells by stem cell factor, Flk2/Flt3 ligand, thrombopoietin, IL-6, and soluble IL-6 receptor. J. Clin. Invest. 105:2000;1013-1021.
15. Gille J., Paxton L.L., Lawley T.J., Caughman S.W., Swerlick R.A. Retinoic acid inhibits the regulated expression of vascular cell adhesion molecule-1 by cultured dermal microvascular endothelial cells. J. Clin. Invest. 99:1997;492-500.
16. Gearing A.J.H., Hemingway I., Pigott R., Hughes J., Rees A.J., Cashman S.J. Soluble forms of vascular adhesion molecules, E-selectin, ICAM-1 and VCAM-1: pathological significance. Ann. N. Y. Acad. Sci. 667:1992;324-331.
17. Gearing A.J.H., Newman W. Circulating adhesion molecules in disease. Immunol. Today. 14:1993;506-512.
18. Hirohata S., Yanagida T., Nampei A., Hashimoto H., Yoshikawa H.et al. Enhanced generation of VEGF and soluble VCAM-1 from CD34+ progenitor cells of the bone marrow in rheumatoid arthritis. Arthritis Rheum. 48:2003;S341. [Suppl.].
19. Eguchi K., Kawakami A., Ida H., Nakashima M., Yamashita I.et al. Bucillamine inhibits T cell adhesion to human endothelial cells. J. Rheumatol. 119:1992;1045-1050.
20. Seideman P., Lindstöm B. Phamacokinetic interactions of penicillamine in rheumatoid arthritis. J. Rheumatol. 16:1989;473-474.
21. Kim J.M., Ho S.H., Park E.J., Hahn W., Cho H.et al. Angiostatin gene transfer as an effective treatment strategy in murine collagen-induced arthritis. Arthritis Rheum. 46:2002;793-801.
22. Nagashima M., Wauke K., Hirano D., Ishigami S., Aono H.et al. Effects of combinations of anti-rheumatic drugs on the production of vascular endothelial growth factor and basic fibroblast growth factor in cultured synoviocytes and patients with rheumatoid arthritis. Rheumatology. 39:2000;1255-1262.
23. Garton K.J., Gough P.J., Philalay J., Wille P.T., Blobel C.P.et al. Stimulated shedding of vascular cell adhesion molecule 1 (VCAM-1) is mediated by tumor necrosis factor-α-converting enzyme (ADAM 17). J. Biol. Chem. 278:2003;37459-37464.
24. Ohta S., Harigai M., Tanaka M., Kawaguchi Y., Sugiura T.et al. Tumor necrosis factor-alpha (TNF-alpha) converting enzyme contributes to production of TNF-alpha in synovial tissues from patients with rheumatoid arthritis. J. Rheumatol. 28:2001;1756-1763.
25. Pelletier L., Regnard J., Fellmann D., Charbord P. An in vitro model for the study of human bone marrow angiogenesis: role of hematopoietic cytokines. Lab. Invest. 80:2000;501-511.